1 / 44

Wipo Regional Workshop on Patent Analytics

Wipo Regional Workshop on Patent Analytics. WIPO & INPI Rio de Janeiro, August 26 a 28, 2013 Samples of Patent Analytics Observatory of Tecnologies - INPI/ Brazil Prof. Adelaide Antunes aantunes@inpi.ufrj.br. OBTEC / INPI. Observatory of Technologies

delano
Download Presentation

Wipo Regional Workshop on Patent Analytics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Wipo Regional Workshop on Patent Analytics WIPO & INPI Rio de Janeiro, August 26 a 28, 2013 Samples of Patent Analytics Observatory of Tecnologies - INPI/ Brazil Prof. Adelaide Antunes aantunes@inpi.ufrj.br

  2. OBTEC / INPI Observatory of Technologies Strategic utilization of IP System in favor of the economic development. Created in 2010, the Observatory stimulates the interaction between Brazilian Office and the several stakeholders of the Brazilian National Innovation System (Universities, Research Institutes, Finance Organizations, Government Agencies)

  3. Wipo Regional Workshop on Patent Analytics Observatory of Tecnologies - INPI/ Brazil It´s necessary to identify the needs To develop a Strategy To search for information To analyse To disseminate University(papers) INPI (Government) Industries Innovation EconomicDevelopment Reports (patents)

  4. Partnership INPI – OBTEC / FINEP(Funding Authority for Studies and Projects) Observatory in the Health Sector COOPERATION AGREEMENT • FINEP –goal: Introduce IP Culture • Brands / Patents

  5. EX.: EMS • Patents Major Generic Drug Company (80% incoming) • Trademarks

  6. STUDIES - DRUGS- FINEP

  7. Ganciclovir • RN: 82410-32-0 • IUPAC: 2-amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6H-Purin-6-one • Therapeutic class: antiviral • Names and brands • 2-Amino-1,9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]6H-purin-6-one • Biolf 62 • BN-B759V • Gansikloviiri • Gansiklovir • Gancyclovir • Gancyklovir • Ganecicilovir • Gansikloviiri • Gansiklovir • HSDB 6512

  8. Ganciclovir • Producers(DWCP) – 38 • China - 24 • Índia - 4 • Alemanha - 3 • Estados Unidos - 2 • Argentina, Brasil, Canadá, França, Itália – 1 • Labs Brasil (DEF) • Roche • Halex Istar • Blausiegel • Lafepe • Eurofarma • N º Priority documents / Country • China - 18 • EUA - 5 • Índia - 5 • Escritório Europeu de Patentes - 2 (Itália e França) • Espanha e a Itália - 1 depósito cada.

  9. Partnership INPI – OBTEC / FIOCRUZOswaldo Cruz Foundation Science at Service of Life Observatory in theHealth Sector COOPERATION AGREEMENT

  10. Partnership INPI (OBTEC) / FIOCRUZ to identify global trends in cancer subsidize decision-making processes in the Brazilian healthcare sector Definition of (Brazilian) priorities • Important to knowthePatentlandscapeoncancerdrugs • not-patentedtechnologies • patentsthathaveexpired

  11. Partnership INPI (OBTEC) / FIOCRUZ 84.351 patent documents related to cancer drugs (worldwide) Derwent Innovations Index

  12. STUDIES

  13. call for papers:International Journal of Molecular Sciences (2013)Trends in Nanopharmaceutical Patents Scientific journal Case Study Adelaide Antunes1, Iolanda Fierro1, Rafaela Guerrante1, Flavia Mendes2 and Maria Simone de M. Alencar3 1INPI; 2UFRJ ; 3FIOCRUZ

  14. Methodology Data Base Derwent Innovations Index Main Advantages The summaries are full of keywords The possibility of exporting the patent documents recovered in the search using software (Vantage Point) The availability of Manual Code related to nanotechnology (classification attributed in the database to all patent documents indexed in it) Selection of documents that were indexed between 2002 and 2012 in the Derwent database

  15. Manual Codes related to nanotechnology applied to the pharmaceutical sector, and the number of patent documents Focus on Special Issue “Bioactive Nanoparticle 2012” Removing the patent document that were in more than one of the nine series

  16. Results

  17. The main patent applicant by area

  18. MIT Partnerships • MIT • nanoparticles for use in encapsulating a biologically active agent (e.g., polynucleotide) Advantage is in effectively providing low immunogenicity and toxicity Universities and Hospitals

  19. Chapter 5 - The Contribution of Information Science through Intellectual Property to Innovation in the Brazilian Health Sector Adelaide Maria de Souza Antunes, Flavia Maria Lins Mendes, Suzanne de Oliveira Rodrigues Schumacher, Luc Quoniam, Jorge Lima de Magalhães Rethinking The Conceptual Base For New Practical Applications In The Information Value And Quality (IGI Global 2014 USA)

  20. Brazil Health System (SUS) Section 1: Pharmaceuticals industry, made up of six groups Group 1 – Antivirals (including antiretrovirals) Group 2 – Neglected Diseases Group 3 – Chronic non-communicable diseases Group 4 – Biological pathways Group 5 – Vaccines and Hemoderivatives Group 6 – Medications and inputs for the treatment of medical issues resulting from nuclear accidents. Section 2: Medical devices and healthcare devices in general

  21. Methodology Database used to access the patent documents: SciFinder Scholar Search for each drug, using the CAS Registry Number Informations patents relating to processes (synthesis and/or formulation); main Applicants (assignees) top countries information about the first patent for the drug, date and respective assignee patents filed in Brazil trends over time of patenting

  22. Atorvastatin • Atorvastatin (CAS RN: 134523-00-5) • 114 process patents • 84 are for its synthesis • 26 for its formulation • 4 for its synthesis and formulation • Companies with the most patents (eight each) • Teva Pharmaceuticals Industries • Warner-Lambert Company • First patent • 1986 Warner-Lambert Company • Brazil (17 deposits) • Warner Lambert Company (five for synthesis and one for formulation) • Teva Pharmaceuticals Industries (one for formulation and one for synthesis) • Pfizer (synthesis)

  23. Calcitonin • Calcitonin (CAS RN: 9007-12-9) • 204 process patents • 169 are for its synthesis • 28 for its formulation • 7 for its synthesis and formulation • Companies with the most patents • Armour Pharmaceutical (USA) - 9 • First patent • 1968 Ciba Ltd (Switzerland) • Brazil (10 patents) • 2 for synthesis by Institut Gustave Roussy (France),

  24. III Academic Intelectual PropertyandInnovationDevelopment Meeting ( III ENAPID - INPI 2010)KeyStructuresonSynthesisof HIV drugsAdelaide Maria de Souza Antunes1, Rodrigo José Ávila Cartaxo2, Flavia Maria Lins Mendes2 Scientific journal 1INPI; 2UFRJ

  25. 19 HIV / SciFinder (CAS/ACS) • Busca: RN • Top Applicants: • Merck & Co - 15 patentes • Bristol-Myers Squibb Co - 10 patentes • Technology domination: • EUA – 40% • China, Índia e Japan – 41% • 54% em PCT

  26. Methodology – 19 HIV

  27. KEY ChemicalSubstancesAnalysis for HIVs 5-Methyluridine Estavudine Zidovudine 2 routes 4 routes • Bristol-Myers (US) and Ajinomoto (JP) • Bristol-Myers, Ajinomoto, Japan Tobacco and China Pharmacy Univ • 24 producers : • 16 China, 2 Canada, 2 USA, 1 Italy, 1 Korea, 1 Slovakiaand 1 Rússia

  28. ThesisLuiz André Felizardo S. Schlittler (EQ/UFRJ)Advisers: Prof. Nei Pereira Jr./ Profa. Adelaide Antunes(INPI) Mapping technological knowlodge of ethanol 2º Generation

  29. Technological focus Produção de etanol 2G Genetic modification micro-organims Enzymatic hydrolysis Midwest R. Inst. Univ. Florida Enzymeproduction Others compounds production

  30. ThesisMaria Simone de Menezes Alencar(EQ/UFRJ)Adviser: Adelaide Maria de Souza Antunes (INPI) Technological Foresight applied nanotechnology

  31. THERMS (strategy) Base de dados: Derwent Innovation Index

  32. Results Top countries

  33. Analysis

  34. Patenting in The US NANOPRODUCTUS: radiografia industrial, sistemas óticos e de imagem NANOPRODUCTUS: com aplicações em computadores, filmes e automóveis NANOINTERMEDIATES: biosensores, dispositivos fotovoltaicos e para armazenamento de memória CLUSTER 1 NANOPRODUCTUSdentais, adesivos e revestimentos dentais e equipamentos ortodônticos.

  35. Estratégia de Inovação e Tecnologia em Sementes. Thesis Rafaela Guerrante (EQ/UFRJ) advisers: Prof. Nei Pereira Jr. e Profa. Adelaide Maria de Souza Antunes Agriculture Innovation Strategy and Technology in Seeds

  36. Case Study – Monsanto’s patents on GURT (genetic use restriction technology) • GURT technology • colloquially known as terminator/traitor technology • causes second generation seeds to be sterile  Terminator • the use of an external chemical inducer which turns "on or off" a plant's genetic traits (ex. sterility)  Traitor • There are not specific keywords/IPCs to describe GURT technology • 1224 Monsanto’s patent documents were retrieved, possibly related to GURT • In order to validate the results and analyze the technologies described in the patents retrieved, a methodology was developed.

  37. Methodology 1st step Reading of TITLE and/or ABSTRACT Reading of CLAIMS and/or DESCRIPTION Reading of CLAIMS and/or DESCRIPTION

  38. Terminator 779 documents “herbicide tolerance” “pest resistance” Filter using AND/OR “tolerance to” DISCARD 14 documents 765 documents NOT RELATED Reading of CLAIMS and DESCRIPTION - (“sterility” OR DO NOT CONTAIN - male (“sterility” OR “sterile”) AND male 9 documents Reading of 8 documents + CLAIMS and DESCRIPTION related to 1 doc. LE - STERILITY NOT RELATED Methodology 2st step “resistance to” “increased grain yield” “increased growth rate” Filt er “sterile”) AND 756 documents 764 docs. MA

  39. Patent and Publications Networks related to Dengue and HPV vaccines: its implications for policy of innovation in health Thesis Priscila Rohem-Santos (IE/UFRJ) Advisor: Claudia Inês Chamas

  40. Survey design and data sources / Analysis The methodology of analysis involves: The search strategy encompasses definition of : • keywords • IPC and Derwent Manual codes • database I – Identification of Dengue and HPV vaccine patent applications and articles; II – Creation of clusters according to various indicators such as applicant, priority number, validity (legal status); III – Claims' analysis of the applications filed in Brazil. IV – Social Network analysis (coauthorsip/ corinventorship)

  41. Survey design and data sources / Analysis (3 databases for articles) (3 databases for patents) Merge results of diferent databases Harmonization of names – Thesaurus Ex.: merges/acquisition of pharamautical industries considering the vaccine sector (Aventis Pasteur + Pasteur Meriex Connaugth = Aventis Pasteur (Sanofi) + Panacea + Shanta = Sanofi Pasteur (Homma et al, 2011) Removal of duplicates Adjacency matrices – correlation of data

  42. RESULTS: HPV articles and patents networks BR

  43. RESULTS: Dengue articles and patents networks Fragility of brazilian researchers’ conection BR

  44. Thanks!!!Adelaide Antunesaantunes@inpi.gov.brElaine Viannaelainev@inpi.gov.brBernanrdoNunesbernardo.nunes@inpi.gov.brCristina D’Urso cmendes@inpi.gov.brPriscila Rohemprirohem@inpi.gov.brRafaela Guerranterafaela@inpi.gov.brobtec@inpi.gov.br

More Related